Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection. — Alzheimer's disease (AD) is the most common cause of dementia, pathologically defined by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles. Recent U.S. Food and Drug...

Evidence span

Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection. — Alzheimer's disease (AD) is the most common cause of dementia, pathologically defined by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles. Recent U.S. Food and Drug...

From Alkhalifa AE et al. 2025, Journal of personalized medicine

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

source-reported model organism

Conditions

— Journal of personalized medicine 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required